Search - tctmd.com

Displaying 1 - 6 of 6

Sort: Relevancy | Date

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

News Conference News TCT 2019

Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT

September 26, 2019

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

News Conference News TCT 2018

More GLOBAL LEADERS: No Benefit of Ticagrelor Monotherapy in New Analyses

Michael O'Riordan

September 24, 2018

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

October 14, 2015

No! Aspirin and Ticagrelor Is a Much Better Option

Presentation TCT 2013

No! Aspirin and Ticagrelor Is a Much Better Option

Presenter: Emmanouil Brilakis

October 28, 2013

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.